SGX-523

DB06314InvestigationalSmall molecule

A MET receptor tyrosine kinase inhibitor.

Mechanism: SGX523 is selective inhibitor of the receptor tyrosine kinase MET. MET is implicated in development and progression of cancer. SGX523 ihibits MET autophosphorylation and signalling, as well as activates cysteine-aspartic acid protease 3 (caspase 3), an enzyme which is part of the apoptosis signalling cascade.
Curator reviewed
Primary indication: Investigated for use/treatment in solid tumors and cancer/tumors (unspecified).Curator reviewed
Formula / weight: C₁₈H₁₃N₇S · 359.408 g/mol (avg)
Also known as: 6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline
Code names: SGX-523

Resolves to

Compound

Structure

InChIKeyBCZUAADEACICHN-UHFFFAOYSA-NSMILESCN1C=C(C=N1)C1=NN2C(SC3=CC=C4N=CC=CC4=C3)=NN=C2C=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with SGX-523, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.